טוען...
Cell-Based Therapies for Stroke: Are We There Yet?
Stroke is the second leading cause of death and physical disability, with a global lifetime incidence rate of 1 in 6. Currently, the only FDA approved treatment for ischemic stroke is the administration of tissue plasminogen activator (tPA). Stem cell clinical trials for stroke have been underway fo...
שמור ב:
| הוצא לאור ב: | Front Neurol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6603096/ https://ncbi.nlm.nih.gov/pubmed/31293500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.00656 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|